Stonegate Capital Partners is hosting a webcast for Palisade Bio (NASDAQ: PALI) to discuss clinical data on LB1148, an investigational treatment of post-surgical abdominal adhesions. The virtual presentation will review the Company's data being presented at the SAGES 2022 Annual Meeting and the need for new pharmaceutical options to prevent post-surgical abdominal adhesions. The live virtual event will begin Wednesday March 16th 2022 at 8:30 am ET and be available by replay. >> Click here to register or attend.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
About Stonegate Capital Partners
Stonegate Capital Partners is a leading advisory firm founded in 1972. We specialize in capital markets advisory with a focus on institutional investor outreach for public and private companies. Our affiliate, Stonegate Capital Markets (Member FINRA/SIPC) provides a full spectrum of investment banking services and equity research.
Contacts:
Erol Girgin
214.987.4121
This email address is being protected from spambots. You need JavaScript enabled to view it.
Source: Stonegate, Inc.
| Last Trade: | US$1.94 |
| Daily Change: | -0.26 -11.82 |
| Daily Volume: | 10,663,816 |
| Market Cap: | US$289.060M |
December 02, 2025 October 28, 2025 October 13, 2025 | |

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load